 However, priority was given to the development of the compound for cutaneous metastases of breast cancer.In 1992 a new research was reported in which the compound was highly effective in mouse against different life cycle stages of different "Leishmania" species, and in fact, more potent than the conventional sodium stibogluconate therapy by a factor of more than 600.Results of the first clinical trial in humans were reported from Indian patients with chronic leishmaniasis with high degree of success and safety.